Six top translational research centers create global alliance; Roche's Burgess joins Bristol;

 @FierceBiotech: Novo Nordisk nabs European OK on blockbuster diabetes drug hopeful. News | Follow @FierceBiotech

@JohnCFierce: As CRL letters go, Impax would seem to have a low hurdle ahead on its sustained release Parkinson's drug. More | Follow @JohnCFierce

@RyanMFierce: Software outfit tackles multi-billion dollar bugaboo in clinical trials. Article | Follow @RyanMFierce

> Scripps Research Institute has joined 5 of the world's top translational research centers to create a new global alliance aimed at strengthening the international academic and non-profit drug development network and accelerating the rate at which "academic research is translated into new medicines." Founding organizations include: The Centre for Drug Research and Development in Canada; Lead Discovery Center, Germany; Scripps; The Centre for Drug Design and Discovery (CD3), KU Leuven R&D, Belgium; Medical Research Council Technology, United Kingdom and Cancer Research Technology, United Kingdom. Release

> Roche ($RHHBY) veteran Mike Burgess has been named senior VP of discovery medicine and clinical pharmacology at Bristol-Myers Squibb ($BMY). Report

> Rexahn Pharmaceutical ($RNN) named Dr. Peter D. Suzdak as its new CEO, replacing Chang Ahn, now chief scientist and chairman of the board. Release

Medical Device News

 @FierceMedDev: J&J device revenue jumped 6.4% in 2012 thanks to Synthes buy. Report | Follow @FierceMedDev

 @DamianFierce: If $LIFE is indeed for sale, that's not stopping it from pursuing more M&A of its own. More | Follow @DamianFierce

> Welch Allyn snags FDA clearance for iPhone-friendly eye scope. Article

> Invacare closes $150M unit sale as it reels from FDA fallout. Story

Pharma News

@FiercePharma: ADHD diagnoses up 24% over past 10 years; study author cites "better diagnosis" and possible "upward trend." More | Follow @FiercePharma

 @AlisonBFierce: Vanderbilt University has emerged as a leading institution for central nervous system drug research and discovery. Editor's Corner | Follow @AlisonBFierce

@EricPFierce: Plant problems stymie Impax NDA for Parkinson drug, FDA says. Article | Follow @EricPFierce

> Amgen's Sensipar scored pricing shield from Congress. News

> Novo ready to rev up Tresiba for European launch. Report

Biotech IT News

> New chief named for Perceptive Informatics. Story

> U.K. regulator finds social media groove…finally. Item

> Software outfit tackles multi-billion dollar bugaboo in clinical trials. Article

> Elsevier rumored as potential buyer of open science startup. News

CRO News

> Is GlaxoSmithKline stretching its contractors too thin? Story

> Covance teams with U.K.'s NHS Trust on Phase I trials. Report

> Clinipace rejiggers eClinical platform. Article

> Quintiles lands pathology accreditation for Indian lab. News

Pharma Manufacturing News

> BASF lands Pronova making it a top omega-3 maker. Report

> Pfizer to develop laser cleaning verification system. Item

> Cargo theft down in year of key arrests. News

> Plant problems stymie Impax NDA, FDA says. Article

Biotech Research News

> Calcium receptor could stop sleeping sickness in its tracks. Item

> Oral breast cancer vaccine could prevent recurrence. Article

> A great leap forward: Microdystrophin gene therapy success in dogs. Report

> Glowing mice could blaze way for detecting, tracking cancer growth. News

And Finally… Investigators at the French Cancer and Aging Research Institute say that in vivo research using mice helped them identify a skin aging regulator. Release

 

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.